---
title: "Contract Development"
description: "Contract development and manufacturing organizations develop and produce drugs and biologics for other companies that prefer not to build their own plants."
canonical: https://www.getswoopr.com/stocks/industries/health-care/contract-development-and-manufacturing-organizations/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Contract Development & Manufacturing Organizations Industry

## Direct Answer

Contract development and manufacturing organizations develop and produce drugs and biologics for other companies that prefer not to build their own plants. Revenue is project-based, with long-term supply agreements for commercial products.

## Industry Overview

Contract Development & Manufacturing Organizations sits within the health care sector. The first numbers to compare across companies here are backlog and book-to-bill; capacity utilization; revenue by modality, such as biologics and cell therapy. The outside forces that move them are listed under Primary Macro Drivers.

## Key Industry Metrics

- **Backlog and book-to-bill**: Backlog is contracted work not yet delivered; book-to-bill compares new orders with revenue recognized. A ratio above one means new orders exceed work completed, pointing to growth; below one suggests the order book is shrinking.
- **Capacity utilization**: Share of available manufacturing capacity actually in use. High utilization supports margins by spreading fixed plant cost, while low utilization points to overbuilt or underbooked facilities.
- **Revenue by modality, such as biologics and cell therapy**: Sales broken out by type of drug produced. Each modality has different margins, customers and growth, so the mix shows where demand is coming from and how exposed results are to one area.
- **Operating margin**: Share of revenue left after plant, labor and overhead costs. Fixed plant cost makes it sensitive to utilization, so a falling margin often tracks idle capacity or start-up costs of new sites.
- **Customer concentration**: Share of revenue from the largest customers or single products. Commercial supply agreements are sticky, but a drop in one product's demand can hit volumes quickly.

## Primary Macro Drivers

- **Biotech outsourcing and funding**: Small biotechs without plants rent capacity from contractors, so more funded biotechs means more projects and a larger backlog.
- **Big pharma capacity needs**: Large drugmakers add outside capacity when their own plants are full, which lifts utilization and supports long-term supply contracts.
- **Growth of biologics and gene therapy**: Biologics and gene therapies need specialized equipment and skills, so growth in these types shifts revenue toward higher-value modalities.
- **Supply-chain reshoring**: Customers seeking nearer or more secure supply move work to local plants, which adds projects and can lift utilization at plants in those regions.

## Major Risks

- **Customer concentration in a few products**: A few products often account for much of a contractor's revenue, so a clinical failure or a lost contract moves results; watch customer concentration and book-to-bill.
- **Facility inspection and quality findings**: Regulators can cite a plant for quality failures, delaying batches and shipments; watch inspection reports, warning letters and any revenue held back.
- **Capacity overbuild**: Building ahead of demand leaves plants underused and depresses margin; watch capacity utilization and whether backlog covers new space.
- **Biotech funding cycles**: When biotech funding is weak, fewer new projects start and some existing ones stop; watch bookings, cancellations and the share of backlog from small sponsors.

## Industry Characteristics

| Characteristic | Profile |
| --- | --- |
| Cyclicality | Mixed |
| Capital Intensity | High |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | Global |

## Companies Associated with Contract Development & Manufacturing Organizations

The SEC's Standard Industrial Classification has no code that describes contract development & manufacturing organizations as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.

| Company | SEC classification | Revenue | Growth | Net margin | Year |
| --- | --- | --- | --- | --- | --- |
| [Charles River Laboratories International, Inc.](https://www.getswoopr.com/stocks/companies/charles-river-laboratories/) | Services-Commercial Physical & Biological Research | $4.0 billion | -0.9% | -3.6% | FY 2025 |
| [West Pharmaceutical Services Inc](https://www.getswoopr.com/stocks/companies/west-pharmaceutical-services/) | Surgical & Medical Instruments & Apparatus | $3.1 billion | 6.3% | 16.1% | FY 2025 |

Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the [company directory](https://www.getswoopr.com/stocks/companies/) and the [health care hub](https://www.getswoopr.com/stocks/industries/health-care/).

## Where to Go Next

The Contract Development & Manufacturing Organizations guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.

### More in Health Care

- [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/)
- [Contract Research Organizations](https://www.getswoopr.com/stocks/industries/health-care/contract-research-organizations/)
- [CNS Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/cns-pharmaceuticals/)
- [Dental Equipment](https://www.getswoopr.com/stocks/industries/health-care/dental-equipment/)
- [Clinical Workflow Software](https://www.getswoopr.com/stocks/industries/health-care/clinical-workflow-software/)
- [Dental Service Organizations](https://www.getswoopr.com/stocks/industries/health-care/dental-service-organizations/)
- [Clinical Trial Technology](https://www.getswoopr.com/stocks/industries/health-care/clinical-trial-technology/)
- [Dermatology Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/dermatology-pharmaceuticals/)
- [Clinical-Stage Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/clinical-stage-biotechnology/)

### Put it to work

- [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)
- [Company research](https://www.getswoopr.com/stocks/companies/)
- [All industries](https://www.getswoopr.com/stocks/industries/)

## Frequently Asked Questions

What are the main KPIs for the Contract Development & Manufacturing Organizations industry?

Key performance indicators for the Contract Development & Manufacturing Organizations industry include: Backlog and book-to-bill; Capacity utilization; Revenue by modality, such as biologics and cell therapy; Operating margin; Customer concentration. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.

How cyclical is the Contract Development & Manufacturing Organizations industry?

The Contract Development & Manufacturing Organizations industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.

What are the biggest risks in the Contract Development & Manufacturing Organizations industry?

The primary risks for Contract Development & Manufacturing Organizations companies include: Customer concentration in a few products, Facility inspection and quality findings, Capacity overbuild, Biotech funding cycles. Investors should assess each company's exposure to these factors and its track record of navigating them.

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).